Chimeric antigen receptor T cell targeting CD44E variant in HCC holds therapeutic potential

models and importantly, did not induce detectable toxicity in vital organs in animal models. Our findings suggested that CD44E-targeting CAR T cell therapy might represent a promising therapeutic approach for HCC treatment.